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Introduction: Patients with heart failure (HF) are now a priority group for cardiac rehabilitation (CR).
A fundamental component of CR is increasing physical ﬁtness through exercise training. Even though studies
show ﬁtness beneﬁts, there is little evidence in routine populations of individual factors that may inﬂuence
ﬁtness. This study aims to evaluate the extent to which demographics and clinical measures predict physical
ﬁtness in patients with HF and develop reference values to guide practice.
Methods: Data from the National Audit Cardiac Rehabilitation (NACR) was analysed. 2047 patients (73% male)
with HF completed an incremental shuttle walk test (ISWT). Backward regression accounting for patient
characteristics and new comorbidity groups were used to identify predictors of distance using ISWT. Reference
values were produced from the percentiles of the ISWT distance.
Results: Population age was 64.43 years (12.39 SD) with an average ISWT distance of 278.57 m (SD 158.57).
Demographics, risk factors and comorbidities explained 26% of the variance in distance (adjusted R2 = 0.256,
p value b 0.001). Diuretics (−33.01 m±8.07 SD) and socioeconomic status (9.12 m±2.91 SD) were signiﬁcant
predictors of baseline walking ﬁtness. Furthermore, respiratory obstructions, musculoskeletal issues and
metabolic diseases were associated with reduced walking distance of 29.8 m, 26.6 m and 18.4 m respectively.
Conclusion: Use of diuretics, socioeconomic status and presence of comorbidities were signiﬁcant predictors of
walking performance in patients with HF who attended CR and were ﬁt enough to carry out an ISWT. Reference
values, to aid clinical practice, were developed that included age, gender and comorbidities status.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Heart failure (HF) is a common chronic cardiovascular condition.
According to the BHF CVD Statistics, over half a million people in the
UK have been diagnosed with HF [1]. Patients with HF experience
marked reductions in their exercise capacity or physical ﬁtness which
has detrimental effects on their activities of daily living, health-related
quality of life and ultimately their hospital admission rate andmortality
[2]. In addition to their heart condition, patients with HF often have the
presence of other chronic comorbidities whichmay further reduce their
physical ﬁtness.
Cardiac rehabilitation (CR) is a safe and effective intervention in the
management of cardiovascular diseases (CVD), which improves
physical ﬁtness, recovery and psychological well-being [3]. A critical
part of the CR programme is exercise training [4]. Based on several
decades of evidence, including a recent Cochrane review [5], the
American College of Cardiology/American Heart Association, European
Society of Cardiology and National Institute for Health and Care Excel-
lence (NICE) [6–8], CR is now highly recommended for HF patients. In
accordance with the recent 3rd edition of BACPR guidelines, this popu-
lation is listed as a priority group who should receive exercise-based CR
as secondary prevention [9].
Improvements in the referral rate of patients with HF to CR have
occurred in recent years, increasing from 7% to 20% from general or
cardiology wards. NICE guidance recommends increasing uptake to CR
through improved recruitment of patients with HF to CR by offering tai-
lored modes of exercise delivery led by a multidisciplinary team [8].
Although clinical trial data on HF exists indicating a relationship in
terms of improvingmaximal exercise capacity through CR. The available
studies tend to be based just on cardiopulmonary exercise testing
(CPET) results amongunique volunteer populations largely represented
by relatively younger males, with fewer comorbidities compared to pa-
tients who participate in CR in routine practice [10,11].
Increasingly sub-maximal ﬁeld tests are being used in clinical
practice with the incremental shuttle walking test (ISWT) being the
most common test in the routine UK CR [10]. It is reliable and strongly
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correlated with CPET results validated in cardiac and pulmonary
populations undergoing rehabilitation programmes [12–15]. Some
studies have used the ISWT to investigate potential determinants of
walking ﬁtness in conventional cardiac populations [16,17] identifying
several personal characteristics as signiﬁcant predictors of ﬁtness,
including gender, age, body mass index, physical activity status, em-
ployment and marital status [15,17,19]. The impact of comorbidities,
which often occur together with the diagnosis of HF, particularly
in elderly patients, have not yet been investigated for their impact
in determining walking ﬁtness in terms of distance achieved using
the ISWT.
The current study aims (1) to investigate and identify, among
patients with HF, any relevant associations between walking ﬁtness
and signiﬁcant patient characteristics, risk factors and comorbidities,
conceptualized in a new classiﬁcation based on similar clinical type,
and (2) to produce HF speciﬁc reference values in terms of distance
achieved using the ISWT.
2. Methods
2.1. Data collection
The analysis used anonymised data routinely collected by the NACR
for patients undertaking CR in England [10]. The electronic data were
acquired from 224 programmes which collect information on patients,
including initiating event, demographic details, risk factors and comor-
bidities, treatments, medications and clinical outcomes pre- and post-
CR. This study included patients who have a diagnosis of HF and were
referred for CR between 1st January 2013 and 30th April 2018.
Maximumwalking distance (in metres) performed during an ISWT,
as a baseline measure of physical ﬁtness recorded during a pre-CR
assessment, represents the dependent variable. The ISWT is a recom-
mended sub-maximal, incremental, externally paced test widely-used
to evaluate exercise capacity [9]: it has 12 levels each one characterised
by a determined speed that increases from 1.9 km/h to 8.5 km/h every
minute. The patient is required to walk along a 10 m course following
the external pace imposed until the end or the stop of the test
[12–15]. The ISWT outcome was analysed in terms of total metres
walked which, as a continuous variable, naturally takes account of the
incremental speed levels. This approach is consistent with robust linear
regression models and also enabled us to create reference values which
are more understandable to clinicians and patients.
2.2. Statistical analysis
Group comparisons were performed using unpaired t-tests. Pearson
correlation coefﬁcientswere used to determine the association between
key continuous variables and ISWT performance. Backward linear
regression models were created to determine which covariates were
associated with ﬁtness expressed as distance walked during the ISWT
at baseline. The analysis accounted for 9 individual covariates and 7
comorbidity-categories.
Variables included in the analysis were based on literature
evidence or relevance in the preliminary analyses. Age (years), gender
(male/female), employment status (employed or retired/unemployed),
marital status (single/partnered) and ethnicity (White/Non-White –
which includes Indian and Black Caribbean) have previously been
shown to inﬂuence outcomes in different CR programmes and were
included in the analysis [15,17,19]. The use of diuretics (no/yes) was
included and taking any loop or thiazide medications was recorded as
being on diuretics, since they have similar effects. Furthermore, the
Multiple Deprivation Index (IMD) status (an England only based
score) was included in the study, investigating relevant inﬂuence on
outcomes. Risk factors, including physical inactivity status at baseline
based on the 150 min/week recommendation from the UK chief medi-
cal ofﬁcer (no/yes), BMI and comorbidities were entered in the study
regression model as they are routinely reported in the NACR annual re-
port [10]. All patient's characteristics were included in the regression
study as independent variables. Statistical level for signiﬁcance was
set at p value b 0.05; variables were included in the ﬁnal regression
model if they respect these criteria. The 25th, 50th and 75th percentiles
of distance walked were developed to provide reference values.
Statistical analysis was conducted using IBM statistical package SPSS
V.25 (SPSS, Chicago, Illinois, USA).
3. Results
The study population included patients with HF who had attended
a CR programme from England and who had undertaken an ISWT
baseline assessment to evaluate physical ﬁtness. The sample consisted
of 2047 patients (73% male) with a mean age of 64.43 years (12.39 SD,
range 19 to 98 years).
Table 1 shows the average ISWT distance in metres for each of the
included variables. The overall mean distance was 278.57 m (158.57
SD). Pearson correlation coefﬁcients indicate a signiﬁcant negative
relationship between age and ISWT distance (−0.379, p value b
0.001). In terms of gender, males covered a greater distance during
the ISWT by an average of 63 m (p value b 0.001). Signiﬁcant associ-
ations were observed between ISWT and physical activity status, BMI
and use of diuretics (all p value b 0.001). Patients who achieved the
weekly physical activity goal of 150 min/week (active subjects)
achieved 66 m greater distance in comparison to those who did not
achieve the 150 min/week threshold at moderate intensity. Patients
with BMI N30 (overweight or obese) walked a shorter distance dur-
ing the ISWT assessment by an average of 33 m less rather than those
with BMI b 30. Patients who were taking diuretics achieve 55 m shorter
distance versus those not taking diuretics. Furthermore, IMD status
was signiﬁcantly associated with ISWT (p value = 0.40) indicating
that there was a gradient across the quintiles, with a greater ISWT
performance from the lowest quintile compared to the 2nd quintile, by
an average of 19 m. No other variables were associated with signiﬁcant
differences in ISWT distance.
Seven alternative categories for grouping comorbidities were cre-
ated and included in this study based on the 18 comorbidities captured
by NACR data. Table 2 shows group comparisons between each of the
comorbidity categories and ISWT walking distance [m]. Patients in-
cluded in the category Ischemia+, Musculoskeletal Metabolic Hyper-
tension and COPD + Asthma perform signiﬁcantly lower on the ISWT.
The mean difference in ISWT performance ranged from 36 and 65 m
(all p value b 0.001) between those who experienced an ischemic
event and those who had musculoskeletal comorbidities, respectively.
Results from the linear regression between ISWT performance and
patient characteristics, risk factors and comorbidities are shown in
Table 3. The regression model indicates that age is negatively correlated
with ISWT walking distance (B =−5.12, ±0.38 SE, p b 0.001). For each
year of increased age above themean, therewas a 5.12mdecrease in dis-
tance covered during the ISWT. Gender was also a strong determinant
of walking ﬁtness; within the model, females achieved an average of
49.41 m (±9.48 m SE) less than their male counterparts (p b 0.001).
Other statistically signiﬁcant associations with ISWT distance included
physical activity, BMI, employment, marital status and use of diuretics.
HF patients who did not achieve the minimum weekly recommended
amount of physical activity, those with higher BMI, unemployed, not in
a relationship and taking diuretics were all associated with a lower
ISWTscore, rangingbetween23and52m(p0.007 tob0.001). In addition,
IMD status had a signiﬁcant and positive association with ISWT perfor-
mance (p value = 0.002). There was an increase of 9.12 m (±2.91 SE)
in ISWT performance for each increment of socioeconomic status
expressed by IMD quintiles. Between all the new studied comorbidity
groups, onlyMusculoskeletal Metabolic and COPD + Asthmawere signiﬁ-
cantly associated with ISWT distance (p 0.032–0.004). The combined
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comorbidity of COPD + Asthma were the strongest determinant of
walking ﬁtness (B =−29.79, ±11.19 SE).
Ethnicity and other comorbidities were not signiﬁcantly associated
with ISWT distance, thus they were automatically removed from the
backward regression analysis. Themodel residualsmet the assumptions
of uniform variance, linearity, with an adjusted R squared value of 0.256
(R= 0.513).
Table 4 shows reference values for patients able to carry out the
ISWT, stratiﬁed by age (≤65 years old–65+ years old), gender and
comorbidity groups displayed in 5th, 25th, 75th and 95th percentiles.
Based on the strength of ﬁndings from the regression, Table 4 sets
out new reference values.
4. Discussion
This study aimed to deﬁne the extent by which demographic and
clinical variables predictedwalkingﬁtness in patientswithHF, addition-
ally, to deﬁne reference values to guide practice.
The mean score that patients with HF achieved during the ISWT is
similar to the 25th percentile of conventional CVD patients with same
mean age attending CR [15]. It is likely that the reason why these
patients are capable of achieving comparable ISWT results despite
their HF condition and the presence of additional comorbidities, is that
the sample is mostly represented by patients with HF classes NYHA I
and II (63%).
Based on the literature, age and gender have an unfavourable im-
pact on walking ﬁtness [15,17,19]. After accounting for the presence
of new-grouped-comorbidities, each one year above the mean age
(64.43 years ± 12.39 SD) and being female were signiﬁcantly
associated with a reduced walking performance of 5.12 m and
49.41 m, respectively.
Another important determinant in walking ﬁtness is the physical
activity status: the regression shows that achieving the weekly goal of
150 min of physical activity at moderate intensity is signiﬁcantly
positive associated with an increased walking distance at the ISWT by
an average of 52.23 m (8.68 SD). The analysis also concludes that
other variables, including BMI (N30), employment status (unemployed)
andmarital status (single) are inversely correlatedwithwalking ﬁtness.
However, the impact of diuretics and IMD status are novel ﬁndings in
this population. According to the regression model, taking diuretics is
Table 2
Group comparison between comorbidity groups and ISWT distance [m].
Comorbidity group ISWT distance in metres [m]
Mean SD Count % Mean
difference
(MD)
p
value
Ischemia+ No 284.87 161.58 1686 82.4 35.769 b0.001
Yes 249.11 140.14 361 17.6
Psychosocial No 280.15 159.27 1782 87.1 12.233 0.241
Yes 267.92 153.65 265 12.9
Musculoskeletal No 295.16 160.42 1528 74.6 65.465 b0.001
Yes 229.70 142.27 519 25.4
Metabolic No 292.92 164.75 1333 65.1 41.138 b0.001
Yes 251.78 142.62 714 34.9
COPD+ Asthma No 285.44 159.51 1750 85.5 47.400 b0.001
Yes 238.04 146.74 297 14.5
Hypertension No 292.67 165.53 1299 63.5 38.584 b0.001
Yes 254.08 142.51 748 36.5
Erectile
dysfunction
No 279.78 159.59 1919 93.7 19.455 0.179
Yes 260.33 141.58 128 6.3
Table 1
Incremental shuttle walk test (ISWT) distance for all included variables.
Patient characteristics ISWT distance in metres [m]
Mean SD Count % Pearson correlation (PC) p value
Age [years] 64.43 12.394 2047 −0.379 b0.001
Patient characteristics ISWT distance in metres [m]
Baseline demographics by distance [m] Mean SD Count % Mean difference (MD) p value
Gender Male 294.91 163.65 1482 72.9 62.877 b0.001
Female 232.03 133.03 552 27.1
Ethnicity White 276.85 156.71 1495 73.0 −6.376 0.42
Non-White 283.22 163.55 552 27.0
Physical activity status No 257.82 153.35 1246 69.4 −65.688 b0.001
Yes 323.51 153.01 550 30.6
Body mass index (BMI) BMI b 30 289.96 162.68 1182 61.8 33.327 b0.001
BMI N 30 256.64 145.75 731 38.2
Diuretics No 305.84 168.99 1033 50.5 55.053 b0.001
Yes 250.78 141.99 1014 49.5
Employment status Employed 272.89 153.61 1335 77.8 −12.841 0.151
Unemployed 285.73 154.08 381 22.2
Marital status Single 270.17 170.21 687 39.3 −9.161 0.233
Partner 279.33 147.81 1062 60.7
Total population ISWT score 278.57 158.57 2047
Patient characteristics ISWT distance in metres [m]
Mean SD Count % F p value
IMD Lowest quintile 260.47 169.15 368 22.3 1.004 0.404
2nd quintile 280.27 161.13 361 21.9
3rd quintile 278.46 154.95 312 18.9
4th quintile 276.63 158.27 314 19
5th quintile 281.01 154.61 295 17.9
Total 274.95 160.14 1650 100
Patient characteristics ISWT distance in metres [m]
Mean SD Count % MD p value
IMD Lowest quintile 260.47 169.15 368 22.3 18.641 0.049
≥2nd quintile 279.11 157.28 1282 77.7
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associated with poorer physical ﬁtness, with a walking distance reduc-
tion by an average of 33.06 m (8.07 SD). This reduced ﬁtness level
may not be directly related to diuretics as it could be inﬂuenced by
other factors such as being overweight or obese and HF severity. For
instance, the proportion of overweight or obese patients was greatest
in NYHA class IV as was the proportion of patients taking diuretics.
We also assessed the extent to which socioeconomic status might
inﬂuence physical ﬁtness among patients with HF. The IMD status was
a signiﬁcant predictor of ISWT performance; a higher socioeconomic
status was associated with a higher ISWT distance. We observed a
9.12 m (2.91 SD) higher walking distance per quintile IMD. The largest
difference in walking distance was observed between the least two
quintiles versus the 5th. This suggests that living in an area with a
high score of deprivation is associated with a poor walking distance.
The concept of grouping comorbidities based on similar clinical cat-
egories appears to be a novel method of understanding the complexity
of HF associated physical ﬁtness. We tended to group under the
same category Musculoskeletal comorbidities such as arthritis,
osteoporosis, rheumatism and chronic back pain since they share a
common inﬂammatory or chronic process that involves muscles and
joints; Metabolic included any type of comorbidity that resulted in
metabolic impairment, including diabetes and hypercholesterolemia/
dyslipidemia; and the COPD + Asthma category any kind of pulmonary
obstruction. The presence of any one of these comorbidity categories
was signiﬁcant in predicting walking ﬁtness in patients with HF. The
most debilitating comorbiditywas COPD+Asthma, whichwas associated
with a 29.79 m (±11.19 SD) reduction in walking distance. Presence
of pulmonary obstruction (irreversible or reversible) results in the
symptom of breathlessness that generally occurs with exertion or at
rest when the condition is severe (COPD) [18]. There were also
signiﬁcant inverse associations with the presence of anyMusculoskeletal
condition, which reduced walking performance in the order of 26.64 m
(±9.34 SD), and Metabolic comorbidities which was associated with an
18.36 m (±8.56 SD) reduction in walking distance. Both of these comor-
bidities,which often are exclusion criteria for clinical trials involving exer-
cise, clearly add to theburden that impairswalking ability in patientswith
HF [5].
Since the presence of this comorbidity, together with demographic
characteristics, signiﬁcantly inﬂuence ﬁtness of patientswithHF,we de-
veloped tableswith reference values categorized by age and gender that
help to better understand the walking capabilities among HF patients
participating in CR, taking into account the impact of different comor-
bidities. This represents a new approach which accounts for the pres-
ence of comorbidities accompanying HF which should enable
clinicians to better understand the exercise capabilities of a given pa-
tient and to assist with the development of an appropriate exercise pre-
scription during CR.
Our ﬁndings have generated new knowledge to guide clinical deci-
sions regarding the suitability of patients with HF and their ability to
participate in CR. The creation of reference values is suggested to
guide the CR team in developing individualized exercise programmes
that are appropriate for a given patient's condition, age, gender and
presence of any comorbidities, and based on their walking capacity at
the beginning of CR.
Table 4
ISWT reference values for HF patients according to age, gender and presence of any signiﬁcant comorbidity groups.
Patient characteristics Mean SD Percentile 05 Percentile 25 Percentile 75 Percentile 95 Count
Young HF ≤65 Male COPD + Asthma 302.17 166.45 70 180 375 670 88
Metabolic 313.49 160.19 80 180 420 630 230
Musculoskeletal 301.15 173.49 30 180 420 630 128
None-of-the-above comorbidities 377.65 180.46 80 250 520 640 356
Female COPD + Asthma 224.44 141.91 60 90 320 520 36
Metabolic 228.14 127.68 60 130 300 520 59
Musculoskeletal 216.76 113.94 60 120 305 420 68
None-of-the-above comorbidities 310.39 150.06 70 210 420 550 140
Old HF 65+ COPD + Asthma 226.30 126.95 50 120 320 490 125
Metabolic 235.91 126.97 60 150 330 420 325
Musculoskeletal 220.20 133.08 50 120 280 450 210
None-of-the-above comorbidities 263.90 144.54 70 170 350 520 291
Female COPD + Asthma 149.35 98.19 30 70 180 350 46
Metabolic 167.54 88.42 40 100 220 330 95
Musculoskeletal 174.21 97.26 40 90 240 340 113
None-of-the-above comorbidities 226.94 118.83 50 140 310 420 121
Table 3
Linear regression ﬁndings for the ISWT by patient characteristics.
Patient characteristics B Std. error t Sig. 95% conﬁdence interval
Lower bound Upper bound
Age −5.115 0.376 −13.587 b0.001 −5.854 −4.376
Gender (female) −49.409 9.476 −5.214 b0.001 −68.003 −30.815
Physical activity status (150 min/week) 52.233 8.677 6.020 b0.001 35.208 69.258
BMI (N30) −34.212 8.561 −3.996 b0.001 −51.009 −17.414
Employment status (unemployed) −47.231 10.862 −4.348 b0.001 −68.545 −25.917
Marital status (partnered) 22.616 8.392 2.695 0.007 6.149 39.084
Diuretics (yes) −33.059 8.071 −4.096 b0.001 −48.895 −17.223
IMD status 9.120 2.907 3.138 0.002 3.417 14.823
Musculoskeletal group (yes) −26.640 9.335 −2.854 0.004 −44.957 −8.323
Metabolic group (yes) −18.357 8.561 −2.144 0.032 −35.156 −1.559
COPD + Asthma (yes) −29.791 11.185 −2.663 0.008 −51.739 −7.844
Constant 623.389 27.27 22.86 b0.001 569.88 676.897
R = 0.513; R2 = 0.264; Adj R2 = 0.256.
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5. Limitations
Although this study investigated a large sample of patients, the ISWT
results are not fully representative of the broader severity of HF typical
of CR programmes. Due to the predominance of NYHA class II (47.7%)
and the small proportion of patients in NYHA class III (25.8%) and IV
(11.3%), the analysis could be biased despite the consideration of co-
morbidity status. Furthermore, although the use of diuretics was a sig-
niﬁcant predictor of walking ﬁtness, we were unable to account for
the dosage of these medications because the NACR does not capture
this information. Diuretics was associated with NYHA class, however,
due to insufﬁcient sample size in the NYHA variable this interaction
could not be included in the regression andwill assessed in futurework.
6. Conclusion
The study has concluded that use of diuretics, IMD status and the
presence of COPD + Asthma, Musculoskeletal and Metabolic comorbidi-
ties are signiﬁcant characteristics strongly associated to walking ﬁtness
in patientswithHF. The creation of reference values for patientswithHF
makes this study unique in that it clariﬁes the extent towhich individual
factors and presence of comorbidities determine walking capability in
terms of distance walked on a baseline ISWT assessment. The develop-
ment of these reference tables permits a better understanding of the
functional capabilities of a patient with HF at the initiation of CR pro-
gramme, and to optimize an appropriate and individualized exercise-
based intervention for a given patient.
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